BioLineRx is trading at $2.95 (up 7.9%), extending its recent rebound amid a broader biotech sector rally and risk-on market sentiment.
- The move follows a general rotation into cyclicals and strength in the XBI biotech ETF, despite a lack of fresh company-specific filings or announcements today.
- Shares continue to build on gains from August 4, when the stock climbed roughly 5.9% on similar market-driven momentum rather than fundamental news.
- The upward trend aligns with broader market strength, as both the Dow and biotech indices trade higher.